Forest Services
Introduction: Semaglutide Uptake and Self-Medication Trends in India
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has seen a rapid increase in use across India since 2021, driven by its dual indication for type 2 diabetes mellitus (T2DM) management and weight loss. According to the IQVIA India Pharma Report 2024, prescriptions for semaglutide increased by 150% between 2021 and 2023. Concurrently, approximately 35% of users reportedly self-medicate without prescriptions (Indian Express, 2024), highlighting a significant public health concern. This surge exposes gaps in regulatory enforcement and pharmacovigilance, demanding urgent policy attention.
UPSC Relevance
- GS Paper 2: Health Governance, Drug Regulatory Frameworks, Consumer Protection
- GS Paper 3: Economic Impact of Pharmaceutical Markets, Public Health Expenditure
- Essay: Challenges in Drug Regulation and Public Health Safety in India
Regulatory Framework Governing Semaglutide in India
The Drugs and Cosmetics Act, 1940 regulates the manufacture and sale of drugs, with Sections 18 and 27 mandating prescription-only sale for certain drugs, including semaglutide. The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 prohibits misleading advertisements, a relevant provision given the proliferation of online claims promoting semaglutide for weight loss. The Indian Medical Council Act, 1956 governs medical practice standards, including prescription ethics. Supreme Court rulings such as Union of India v. Association for Democratic Reforms (2002) emphasize consumer protection and drug safety, reinforcing the need for strict regulatory compliance. However, enforcement remains weak, as evidenced by only 45% pharmacy compliance with prescription sale norms (CDSCO Market Surveillance 2023).
- CDSCO is the principal drug regulator responsible for approvals and market surveillance.
- Pharmacovigilance Programme of India (PvPI) monitors adverse drug reactions (ADRs), reporting a 60% rise in semaglutide-linked ADRs in 2023.
- MoHFW formulates health policies but lacks integrated digital enforcement mechanisms.
- FSSAI regulates supplements but does not cover pharmaceutical drugs like semaglutide.
- ICMR conducts research on drug efficacy and public health impact.
Economic Dimensions of Semaglutide Use
India's anti-diabetic drug market was valued at approximately USD 3.5 billion in 2023, with semaglutide contributing to a 25% annual growth rate (IQVIA India Pharma Report 2024). Pharmaceutical companies reported a 40% increase in semaglutide sales post-2022 (PharmaBiz 2024). Despite market growth, rising self-medication drives up out-of-pocket expenditure, which constitutes 62% of total health spending (National Health Accounts 2021-22). Unsupervised use risks adverse effects, potentially increasing the public health system's cost burden. Additionally, India’s import dependency on semaglutide active pharmaceutical ingredients (APIs) exacerbates trade deficits.
Health and Safety Concerns from Self-Medication
Self-medication with semaglutide bypasses clinical evaluation, increasing risks of adverse events such as gastrointestinal disturbances, pancreatitis, and hypoglycemia. The Pharmacovigilance Programme of India reported a 60% increase in adverse drug reaction reports related to semaglutide in 2023 compared to 2022. The lack of real-time digital prescription monitoring enables pharmacies to sell semaglutide over-the-counter, contravening regulatory provisions. Obesity prevalence at 7.3% among Indian adults (NFHS-5, 2019-21) fuels demand for weight loss drugs, often leading consumers to self-medicate without adequate medical guidance.
Comparative Analysis: India vs United States on Semaglutide Regulation
| Aspect | India | United States |
|---|---|---|
| Regulatory Act | Drugs and Cosmetics Act, 1940 | Food, Drug, and Cosmetic Act, 1938 |
| Prescription Enforcement | 45% pharmacy compliance; OTC sales prevalent | Strict prescription-only; REMS programs enforce controlled use |
| Pharmacovigilance | PvPI monitors ADRs; rising adverse events | FDA Drug Safety Communications; lower ADR incidence |
| Self-Medication Incidence | ~35% semaglutide users self-medicate | Significantly lower due to regulatory controls |
| Adverse Event Rate | 60% increase in ADRs (2023 vs 2022) | 30% lower ADR incidence than India |
Critical Gaps in India's Drug Regulation and Enforcement
- Absence of integrated, real-time digital prescription monitoring systems enables unauthorized semaglutide sales.
- Inadequate enforcement of existing laws, with low pharmacy compliance to prescription-only sale norms.
- Lack of public awareness campaigns on risks of self-medication and drug misuse.
- Limited coordination between CDSCO, PvPI, and state drug authorities impedes effective surveillance.
- Regulatory ambiguity between pharmaceutical drugs and supplements exploited by online platforms to market semaglutide.
Way Forward: Policy and Regulatory Interventions
- Implement a nationwide digital prescription monitoring system to track semaglutide dispensing in real time.
- Strengthen enforcement of the Drugs and Cosmetics Act, 1940 with penalties for non-compliant pharmacies.
- Expand pharmacovigilance capacity under PvPI for proactive adverse event detection and reporting.
- Launch targeted public awareness campaigns on the dangers of self-medication with semaglutide.
- Enhance inter-agency coordination among CDSCO, MoHFW, and state regulators for unified policy action.
- Encourage domestic API manufacturing to reduce import dependency and stabilize supply chains.
- The Drugs and Cosmetics Act, 1940 mandates prescription-only sale of semaglutide.
- The Drugs and Magic Remedies Act, 1954 allows advertising of semaglutide for weight loss.
- The Pharmacovigilance Programme of India monitors adverse drug reactions related to semaglutide.
Which of the above statements is/are correct?
- Self-medication with semaglutide is estimated at around 35% of users.
- India has a real-time digital prescription monitoring system for semaglutide.
- Adverse drug reactions related to semaglutide increased by 60% in 2023 compared to 2022.
Which of the above statements is/are correct?
Jharkhand & JPSC Relevance
- JPSC Paper: Paper 2 (General Studies - Health and Social Issues)
- Jharkhand Angle: Rising obesity and diabetes prevalence in Jharkhand increases demand for anti-diabetic drugs, including semaglutide, with similar self-medication risks.
- Mains Pointer: Discuss state-level enforcement gaps, need for awareness campaigns, and integration with national pharmacovigilance efforts.
What is semaglutide and its approved uses?
Semaglutide is a GLP-1 receptor agonist used primarily for managing type 2 diabetes mellitus and obesity-related weight loss. It improves glycemic control and reduces appetite.
Which Indian law regulates the sale of semaglutide?
The Drugs and Cosmetics Act, 1940 regulates the manufacture and sale of semaglutide, classifying it as a prescription-only drug under Sections 18 and 27.
What are the risks associated with self-medication of semaglutide?
Self-medication risks include adverse effects like pancreatitis, hypoglycemia, gastrointestinal issues, and lack of medical supervision leading to misuse and delayed diagnosis of complications.
How does India's semaglutide regulation compare with the US?
The US FDA enforces strict prescription controls with REMS programs, resulting in lower self-medication rates and adverse events, unlike India where enforcement and monitoring are weak.
What role does the Pharmacovigilance Programme of India play?
PvPI monitors adverse drug reactions nationwide, collects safety data, and issues alerts to ensure drug safety, including for semaglutide.